
|Articles|April 23, 2004
FDA grants market approval for Hylaform
Inamed Corp. announced that the U.S. Food and Drug Administration has granted market approval for Hylaform, a hyaluronic acid-based dermal filler that is indicated for injection into the mid to deep dermis for correction of moderate to severe facial wrinkles and folds.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
First-in-Class Topical GT20029 Demonstrates Promising Phase 2 Efficacy and Tolerability for AGA
2
Highlighting Major Breakthroughs for Atopic Dermatitis and Psoriasis in 2025
3
Expert Panel Unanimously Backs DecisionDx-Melanoma for Guiding Personalized Cancer Care
4
Considering Biologics and Shared Decision-Making in Moderate to Severe Plaque Psoriasis: Part 2
5

















